Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML

A Kongruang, N Limsuwanachot, S Magmuang… - …, 2023 - Taylor & Francis
Objectives We performed a feasibility study of an FDA-approved commercial ddPCR assay
to measure BCR:: ABL1 in CML patients treated using TKI therapy. Methods Assay …
被引用次数：4 相关文章

Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML.

A Kongruang, N Limsuwanachot… - Hematology …, 2023 - europepmc.org
Objectives We performed a feasibility study of an FDA-approved commercial ddPCR assay
to measure BCR:: ABL1 in CML patients treated using TKI therapy. Methods Assay …

Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR:: ABL1 transcripts in tyrosine kinase inhibitor treated CML

A Kongruang, N Limsuwanachot… - Hematology …, 2023 - mahidol.elsevierpure.com
Objectives: We performed a feasibility study of an FDA-approved commercial ddPCR assay
to measure BCR:: ABL1 in CML patients treated using TKI therapy. Methods: Assay …

Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR:: ABL1 transcripts in tyrosine kinase inhibitor treated CML

A Kongruang, N Limsuwanachot… - Hematology …, 2023 - pubmed.ncbi.nlm.nih.gov
Objectives We performed a feasibility study of an FDA-approved commercial ddPCR assay
to measure BCR:: ABL1 in CML patients treated using TKI therapy. Methods Assay …